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Finding and characterizing Partially Methylated 
Domains in human haematopoietic cells 
Martí Duran Ferrer 
DNA cytosine methylation has been demonstrated to be a central epigenetic modification that has essential 
roles in a myriad of cellular processes. Some examples of these include gene regulation, DNA-protein 
interactions, cellular differentiation, X-inactivation, maintenance of genome integrity by suppressing 
transposable elements and viruses, embryogenesis, genomic imprinting and tumourigenesis. This list is 
increasingly growing thanks to recent advances in genome-wide technologies, like Whole Genome Bisulfite 
Sequencing (WGBS-Seq). The development of this technology in research has allowed the identification of 
new features of the DNA methylation landscape that was not possible using previous technologies, like 
Partially Methylated Domains (PMDs). PMDs have been found in several cell lines, as well as in both 
healthy and cancer primary samples. They have been described as regions with high variability in 
methylation levels across individual CpG sites and intermediate methylation levels on average with respect 
to the genome. Here, we performed an extensive search of PMDs in a big dataset of different haematopoietic 
primary cells from both myeloid and lymphoid lineages. We found and characterized significant PMDs in 
plasma B cells, confirming that PMDs are a phenomenon that is restricted to certain differentiated cells. 
Additionally, we found loci aberrantly hypomethylated in a myeloma sample which overlapped with plasma 
B cell PMDs. Genome-wide comparison of the myeloma and plasma B cell sample revealed that this is 
probably also the case for other loci. 
 
INTRODUCTION 
DNA methylation is a very common epigenetic 
mark, which involves a covalent attachment of a 
methyl group to the C5 position of the cytosine 
ring (Cedar H, 2009). The enzymes responsible 
for the methylation are grouped in the family of 
DNA methyltransferase enzymes DNMT (Okano 
M, 1998), namely the catalytic active DNMT1, 
DNMT3A and DNMT3B, and DNMTL3, a 
catalytic inactive homologue to both DNMT3A 
and DNMT3B. 
 Each of the catalytically active DNMTs, 
have been demonstrated to be crucial for 
embryonic development, and the complete 
ablation of methylation provokes embryonic 
lethality (Li E, 1992; Okano M, 1999). DNMT1 
is thought to be principally involved in the 
maintenance of pre-existing methylation, and 
DNMT3A and DNMT3B act as de novo 
methyltransferases, modifying unmethylated 
DNA. Embryonic stem (ES) cells lacking both 
DNMT3A and DNMT3B progressively lose 
differentiation potential with cell passage, 
although the potential for self-renewal is 
maintained (Cheng T, 2003). Additionally, recent 
evidence shows that DNMT1 is necessary for self-
renewal of Haematopoietic Stem Cells (HSC), and 
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also for its differentiation pattern, since its 
depletion promotes a dominant myeloid cell 
development (Trowbridge J.J, 2009; Bröske 
A.M, 2009). Finally, DNMT3A has been recently 
demonstrated to be essential for haematopoietic 
stem cell differentiation (Challen GA, 2011). 
Collectively, these studies highlight the 
importance of DNA methylation for normal 
embryo development and cell fate commitment. In 
addition to this, DNA methylation has been 
demonstrated to play a major role in many 
diseases, for example in cancer (Hanahan D, 
2011). The transcriptional start sites (TSS) of 
many genes encoding tumour suppressor genes 
have been found to be hypermethylated in cancer, 
for example retinoblastoma associated protein 1 
(RB1), MLH1, p16 and BRCA1 (among others). 
This hypermethylation at TSS of tumour 
suppressor genes has been found to lead to gene 
silencing, thus promoting cancer progression 
(Esteller M, 2008).  
 However, until recently, much of the work 
on DNA methylation in mammals has been 
focused on the 5-methylcytosine in the CpG 
sequence context, especially in CpG Islands (CGI) 
(regions with higher CpG density than expected) 
and at TSS. This work began in the middle of 80’s 
with the studies of Holliday R, 1975 and Riggs 
AD, 1975. In those studies, the authors suggested 
that DNA sequences could be methylated de novo 
by certain enzymes, that methylation could be 
inherited through somatic cell divisions and that 
DNA methylation directly silences genes. 
Although some of these claims hold true, the role 
of the DNA methylation in gene regulation has 
been demonstrated to be challenging to unravel. 
Recent improvements in genome-wide sequencing 
technology have shed light on new epigenetic 
mysteries, far beyond those of classical DNA 
methylation studies on a single locus. For 
example, DNA methylation located in the vicinity 
of TSS obstructs transcription initiation, but 
methylation in gene body not only does not block 
transcription, but might even favours transcription 
elongation. Even more excitingly, new evidences 
indicate that DNA methylation in gene bodies 
could regulate splicing (Jones PA. 2012). Also, 
methylation in other sequence contexts than CpG, 
namely CHG or CHH (where H is A or T), have 
been proved to be widespread in plants and fungi 
(Cokus SJ, 2008; Rountree MR, 1997) and have 
been recently reported in H1 human embryonic 
stem (Lister R, 2009). Additionally, differentially 
methylated sites have also been reported in 
contexts other than CGIs, called CpG islands 
shores (Irizarry RA, 2009). Also, other types of 
methylation have been reported such as 5-
hydroximethylation of 5C of cytosine (Pastor 
WA, 2011). 
 Furthermore, new methodologies in the 
study of DNA methylation have facilitated the 
finding of new phenomena at many different 
scales in human methylomes. Some examples are 
DNA methylation Valleys (DNMVs) (Xie W, 
2013), Unmethylated, Lowly Methylated and 
Fully Methylated Regions (UMR, LMR and 
FMR) (Stadler MB, 2011) or Partially 
Methylated Domains (PMDs). PMDs were first 
described by Lister R et al (2009) as regions of 
intermediate methylation levels with a mean of 
153kb, constituting a medium-large scale 
methylation phenomenon. The authors found them 
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in differentiated cells (IMR90 lung fibroblasts) 
but not in human embryonic stem cells (H1-ESC). 
Since then, numerous studies have demonstrated 
their presence in different cultured and cancer cell 
lines, including foreskin fibroblasts (FF) and 
Adipose derived stem cells (ADS) (Lister R, 
2011), SH-SY5Y neuroblastoma (Schroeder DI, 
2011) and human mammary epithelial cells 
(HMEC) (Hon GC, 2012). They also have been 
found in human sample tumours (Marzese DM, 
2014; Hovestadt V, 2014; Berman BP, 2011 
and Hansen KD, 2011), and finally, PMDs have 
been reported in human placenta (Schroeder DI, 
2013), representing the first human uncluttered 
and non-cancer tissue type having PMDs. Thus, 
PMDs are emerging as a new feature in 
methylation landscapes that cover huge portions 
of the genome, and their characterization is of 
paramount importance to understand their role in 
health and disease.  
 In this study, we systematically searched 
for PMDs in several haematopoietic primary cells 
included in myeloid and lymphoid branches. We 
found that PMDs were prominent in the lymphoid 
branch and in particular in terminally 
differentiated B cells, plasma B cells (plBC). 
Impressively, PMDs found in plasma B cells 
covered about 70% of the genome representing 
the second human uncultured and non-cancerous 
tissue type reported to have PMDs. We show that 
plBC-PMDs coincide with histone modification 
marks associated with heterochromatic regions, 
and are strongly depleted for active genes and 
DNAse hypersensitivity sites (DHS). 
Additionally, they are regions showing depletion 
of CpG Islands (CGI), a moderate enrichment in 
Lamina Associated Domains (LADs) and no 
enrichment for any particularly repetitive element. 
Gene Ontology (GO) enrichment analysis of 
Biological Processes (BP) in genes present in 
PMDs revealed enrichment in developmental, cell 
fate and morphogenesis biological processes. 
Finally, we describe a locus in which plBC-PMDs 
overlapped with hypomethylated regions in a 
hypomethylated myeloma sample, with lamina 
associated domains (LADs), and with late 
replication regions. Our study adds new evidence 
to the growing body of literature for PMDs as an 
important feature of human methylomes. 
Understanding how these large domains are 
formed, what their functions are and how they are 
maintained through cell divisions will be of 
paramount importance to understand normal cell 
fate commitment, differentiation, development 
and ultimately its role in health and diseases like 
cancer. 
RESULTS 
Finding PMDs across haematopoietc cell 
types.  
We have analysed WGBS-Seq of a series of 
haematopoietic samples in the context of the 
generated BLUEPRINT epigenome project 
(Adam D, 2012). Samples included cells at 
various stages of myeloid and lymphoid 
commitments, and a B cell differentiation dataset 
(Supplementary Table 1). Additionally, we 
included data from a very recent study (Hansen 
KD, 2014), in which the authors found 
hypomethylated regions associated to the 
infection of EBV to B-cells.  
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 To search PMDs in this huge dataset, we 
took advantage of a recently published algorithm 
available as the MethySeekR package (Burger L, 
2013, Materials and Methods). Briefly, the 
algorithm estimates the distribution of polarized 
(unmethylated, fully methylated) and intermediate 
methylation values across a small training set 
(sliding window on chr22) and applies a two-state 
HMM to segment the genome into PMDs and 
non-PMDs
(sexual chromosomes were removed from the 
analysis to avoid confounding effects of imprinted 
genes). After applying the software to our dataset, 
we did only confidently found PMDs in one of the 
samples, the plBC (B cell differentiation dataset) 
(Supplementary Figure 1A-C, Materials and 
Methods, Figure 1). This can be explained by 
two plausible reasons: First, the majority of the 
mammalian published methylomes are divided in 
a fully methylated state and an unmethylated one, 
and do not contain a significant amount of 
intermediate DNA methylation (Lister R 2009 
and Burge L, 2013). Consequently, this polarized 
distribution of DNA methylation throughout the 
genome departs from the search of the algorithm, 
which looks at regions with high variability in the 
methylation levels (and an average intermediate 
methylation). Second, although some of samples 
from Hansen KD et al, (2014) displayed some 
preliminary parameters indicative for PMDs 
presence in the methylome (i.e., a bimodal or 
long-tailed distribution of α-values with a 
significant fraction of windows with α > 1, see 
Materials and Methods), we discarded those 
results, since the data was sequenced at low 
coverage, below the desired one to use the 
algorithm. Consequently, from there on, we 
focused or analysis of PMDs in plasma B cells in 
the context of B cell differentiation dataset.  
Global loss of methylation upon 
differentiation. 
One implication of finding PMDs in a particular 
genome, is that it has to have regions with on 
averaged low methylation values and high 
variability of methylation (Burger L, 2013). 
Thus, given that we have only found PMDs in the 
plasma B cell, which is the most differentiated 
cell type, it suggests that progenitor B cell have 
lost methylation through differentiation. Indeed, 
when we plotted CpG pairwise genome-wide 
comparisons of the levels of methylation between 
PBC and the other samples of the B cell 
differentiation dataset, we clearly appreciate this 
global loss of methylation during cell 
differentiation (Figure 2 and Figure 1). This is in 
agreement with some other studies of  
Figure 1. Density distribution of methylation of PBC, 
plBC, and the PMDs found in plBC and outside of 
PMDs. PBC do not show intermediate methylation, 
which is in contrast to plBC (marked with red 
rectangle). PMDs regions contain an increase in those 
intermediate levels of methylation and, importantly, 
outside PMDs it can be shown a depletion of those 
levels which resembles the PBC genome. PBC, 
Progenitor B Cell, plBC, plasma B Cell, respectively. 
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hematopoietic cells showing global loss of 
methylation upon differentiation and cell fate 
commitment (Ji H, 2010; Kulis M, 2012). 
Characterization of plBC-specific PMDs. 
Once we found regions of partially methylation in 
the plasma B cell genome, we sought to 
characterize them. Examination of the PMDs, 
revealed that they covered about 70% of plasma B 
cell genome, spanning from 0,8kb to 22MB, with 
a median of 50kb and a mean of 245kb, which are 
metrics greater than those of the first report 
(Lister R, 2009). In fact, within the plBC genome 
these domains were visible at chromosome level 
(Supplementary Figure 2). Surprisingly, PMDs 
are not homogeneously distributed across the 
genome, but range from 38% of chromosome 22 
to 83 % of chromosome 21 (Supplementary 
table 2). This difference in coverage of each 
autosome can not be explained by the different 
global levels of GC content of each chromosome ( 
Pearson’s correlation of -0.096, adjusted R2=0.04, 
Supplementary Figure 3). Thus, we speculate 
that PMDs in plBC genome are domains which 
can be involved in many genomic contexts, from 
small-scale phenomena like promoters or 
transcription start sites, to large-scale ones, like 
LADs or LOCKs (Gulen L, 2008; Wen B, 2009). 
However, for a simplistic approach we followed 
our analysis with the whole set of PMDs, 
including PMDs of all sizes. 
 Next, to get insights into the functionality 
of these regions, we examined the enrichment of 
various chromatin states inside and outside of 
PMDs. We used the chromatin segmentation data 
of the lymphoblastoid cell line GM12878 (Ernst, 
J, 2011) available at UCSC Genome Browser 
(Kent WJ, 2002). We performed two different 
combinations of enrichment analysis: First, we 
 
Figure 2. Global methylation loss during B cell differentiation. PCB loss methylation in CpGs upon differentiation. 
This loss is more accentuated form GCBC onwards.  PBC (progenitor B cell), preBC (pre B cell), NBC (Naïve B cell), 
GCBC (Germinal center B cell), MBC (Memory B cell) and plBC (Plasma B cell), The bars show the density of CpGs 
methylation.  
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calculated the proportions of each chromatin state 
in PMDs and outside PMDs, and compared them 
with the coverage across the whole genome. 
Second, we compared chromatin segments inside 
PMDs vs segments outside PMDs (Figure 3). 
Compared to the entire genome, we found that 
PMDs are strongly depleted of gene activity 
(Figure 3, left table). We also found that they 
reside primarily in heterochromatic regions. 
Conversely, outside PMDs showed an enrichment 
in states related to gene activity, supported by the 
enrichment of states like “Active Promoter” or 
“Transcription Associated”, and a large depletion 
of heterochromatic regions (Figure 3, central 
table). The direct comparison between the two 
groups highlighted the differences even stronger 
(Figure 3, right table). Finally, to get clearer 
insights into the establishment of those PMDs, we 
looked at the chromatin states of human 
embryonic stem cell precursor (H1-hESC) in 
PMDs regions found in the plBC genome. This 
comparison revealed that PMDs were regions in 
H1 undergoing extensive transcription and 
extremely depleted of histone repressive marks 
associated with heterochromatin (Supplementary 
Table 3). 
 Following the notion that PMDs represent 
heterochromatic transcriptionally inactive regions, 
we sought to support our analysis by examining 
the overlap of PMDs regions with DNAase I 
hypersensitivity sites (DHS). DHS are regions 
which have an accessible chromatin state 
(Thurman RE, 2012), representing another mean 
to further decipher the functional signature of 
PMDs regions. We found that DHS was 2.3 times 
depleted in PMDs compared to plBC genome, 
whereas they are 2.15 enrich outside PMDs 
(compared to the genome). Directly compared we 
found DHS 5.3 times enrich inside PMDs 
compared to regions outside PMDs. This further 
suggests that PMDs are regions with low gene 
activity (Supplementary table 4). 
  Next, we sought to determine the 
presence of CpG Islands (CGIs) in PMDs. CGIs 
are regions found in the 5’ region of the majority 
of human genes, and are related to the regulation 
of the preceding genes (Illingworth RS, 2009). 
We found a depletion in CGIs in PMDs compared 
to the plBC genome (2.3 fold), and about the same 
amount of enrichment outside of PMDs. Again, 
comparing  PMDs and regions outside of PMDs 
 
Figure 3. Distribution and enrichment analysis of chromatin states in PMDs and OUT PMDs groups compared to 
plBC genome (left and central table) and with themselves (right table). Numbers inside each cell represent the 
percentage of each feature in each group. The colors represent the log2 fold change enrichment of PMDs with respect to 
the group compared. 
Figure 3. Enrichment analysis of PMDs and OUT PMDs groups compared to plBC genome (left and central table) 
and with themselves (right table). Numbers inside each cell represent the percentage of each feature in each group. The 
colors represent the log2 fold change of the groups comparisons. 
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Figure 4. Top: Single CpG methylation of an amplified locus of plBC genome 
containing PMDs. Middle figures: same region as plBC is displayed for the 
hypomethylation myeloma, with UCSC genome browser annotation under 
them. Bottom left: CpG genome-wide comparison of methylation between 
plBC and hypomethylated myeloma. PMDs in plBC displayed in chr10 region are 
aberrantly hypomethylated in hypomethylated myeloma. Those regions are marked 
by heterochromatin marks (e.g H3K27me3) and depleted for active (H3K27ac), are 
late replicating regions and contain LADs. Looking at genome-wide comparison, 
this might be the case for other locis with partially methylated state in plBC and 
hypomethylated in this cancer sample (Red rectangle). 
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against each other, revealed difference, - a 5-fold 
depletion of CGIs in PMDs (Supplementary 
table 5). Interestingly, the number of CpGs, the 
length of CpGs and the GC content in CGI in each 
group did not show any clear difference 
(Supplementary Figure 4).  
 Then, since a significant proportion of 
PMDs are very large (data not shown), we sought 
to determine if these regions overlap with Lamina 
Associated Domains (LADs). These domains are 
large regions (0.1-10MB) that are characterized 
by low gene-expression levels and represent zones 
of contact between chromosome and the nuclear 
lamina (Guelen L, 2008). Thus, given that LADs 
are regions rich in heterochromatin and have poor 
gene expression, we sought to determine whether 
PMDs were enriched in LADs. We found that 
LADs cover about 42% of the plBC genome and 
in PMDs about 49%. Conversely, outside PMDs 
they only covered 27%. Finally, comparing PMDs 
and regions outside PMDs revealed an increase of 
76% of LADs. This data suggest that PMDs have 
a moderate enrichment in LADs (Supplementary 
table 6), although we suggest that this enrichment 
becomes greater when filtering PMDs of larger 
sizes (discussed hereafter and data not shown). 
Afterwards, we asked if PMDs regions were 
enriched in any particular repetitive element, since 
heterochromatic regions are rich in repetitive 
elements. In general, we found instead the same 
proportions of repeat elements in PMDs with 
respect to the genome, although some of them 
showed a slight increase or depletion. The same 
was true for elements in regions outside of PMDs 
with the exception of Satellite elements, which 
showed depletion with respect to the genome and 
also to the PMDs. (Supplementary table 7). 
 Following the functional characterization, 
we next sought to determine the biological 
processes (BP) related with PMDs. To do so, we 
performed an Gene Ontology (GO) enrichment 
analysis of BP of curated Refeq mRNA genes 
belonging to three different groups: First, we 
selected genes totally overlapping PMDs, second 
the same but for genes that fell outside PMDs, and 
finally, we selected those genes overlapping the 
border of PMDs. It has been demonstrated that the 
border of LADs can be enriched in promoters of 
genes being transcribed outside of LADs (Guelen 
L, 2008). Although we did not found an 
astonishing enrichment of LADs in PMDs 
(although the enrichment becomes larger if one 
filters for large PMDs), we wanted to explore 
PMD boundaries to see if there was any trace of a 
possible enrichment in a particular BP for those 
genes. We found 14246 Refseq mRNA genes 
inside PMDs, 26358 outside PMDs and 8959 at 
PMDs borders, confirming that PMDs are regions 
depleted of genes. Interestingly, we found an 
impressive enrichment in functional gene 
annotations related to development and cell fate 
commitment in PMDs (e.g. “multicellular 
organismal development”, “cell fate commitment” 
and “stem cell differentiation”) (Supplementary 
Table 8). Conversely, outside of PMDs, we did 
not find any BP related to development, but the 
majority were related to cell activity (e.g. “cell 
cycle”, “DNA damage checkpoint”, etc.) and also 
to the immune system, like “immune response-
activating signal transduction”, different BPs 
associated with toll-like receptors or MHC-II. 
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(Supplementary Table 9). On the other hand, for 
genes overlapping the borders of PMDs, we found 
more variability in BPs, thus it is likely that those 
genes are not a separate category 
(Supplementary Table 10).  
PMDs in cancer. 
We found and characterized PMDs in a genome-
wide manner. However, we wanted to investigate 
the phenomena in a locus specific manner. Thus, 
we visualized the methylation status of single 
CpGs in a 10 Mb region on chromosome 10, a 
region previously analysed in fibroblast (IMR90 
cell line) by Gaidatzis D, (2014) (Figure 4, top). 
We found a high concordance of PMDs published 
by that study and our data in that region (80% of 
overlap), although plBC-PMDs were larger than 
those in IMR90, in agreement with the greater 
overall coverage of PMDs in the plBC genome. 
Accordingly, we found that in the plBC genome 
the methylation levels in PMDs were also highly 
variable (Figure 4, top), suggesting that this 
variability in the methylation accompanied by 
intermediate average methylation levels might be 
the most distinctive features of these domains, and 
thus this should be taken into account when 
searching for them. Curiously, when visualizing 
the same region in a hypomethylated myeloma 
sample, we found regions where PMDs coincided 
with hypomethylated regions in cancer (Figure4, 
middle). As we have found previously with our 
genome-wide analysis (Figure 3), PMDs in this 
loci also coincided with histone modifications 
associated with repressive chromatin states 
(H3K27me3) and with a depletion in histone 
modifications related to gene active regions 
(H3K27ac) (Figure 4, middle bottom). 
Furthermore, they were depleted of CpG islands 
and DHS. Interestingly, these PMDs also 
coincided with LADs and with regions that 
replicate late in the cell (Figure 4, middle 
bottom). Importantly, the overlap of 
hypomethylation in the myeloma and the PMDs in 
plBC might not only be the case for the genomic 
loci shown, but the same might hold true for other 
genomic regions which display partial 
methylation levels in the plBC genome and 
hypomethylation in the hypomethylated myeloma 
cancer (Figure 4, bottom left). 
DISCUSSION 
Almost 5 years have passed since the first human 
base-pair resolution methylome was published, 
and during these years, a plethora of new 
methylation landscapes have been described, 
including PMDs. Here, we performed an 
extensive search for PMDs in haematopoietic 
methylomes including cells from both myeloid 
and lymphoid branches. We only found PMDs in 
a single cell type, plBC, which represents the most 
differentiated cell of the B cell lineage. 
Importantly, this is the second report of PMDs in 
human uncultured and non-cancerous tissue type, 
suggesting that PMDs might be also methylation 
phenomena of adult tissues and not only of 
developmental tissues (Schroeder DI, 2013). We 
found that the plBC genome is covered by almost 
70% of PMDs and they are unequally distributed 
along the genome and range from 0,8kb to 22Mb 
in size (with a median of 50kb and a mean of 
245kb). Those metrics are greater than those 
originally reported by Lister R, 2009. However, it 
should be noted that Lister R, 2009 used a 
different approach to find PMDs in the IMR90 
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and H1 cell lines, calculating average methylation 
levels in sliding windows across the genome and 
selecting for regions with methylation values less 
than 0.6 or 0.7. As demonstrated here and in 
Gaidatzis D et al (2014), PMDs are domains with 
high variability in methylation which is not taken 
into account by the sliding window approach. 
Thus, it might be the case that using a sliding 
window approaches regions could be wrongly 
identified as PMDs (for example, imprinted 
regions). In any case, those differences in the 
approaches to find PMDs should be borne in 
mind, and they might influence the differences in 
the metrics found in those other studies. Another 
possible explanation is the fact the other studies 
were primarily made on cluttered cells rather than 
on primary tissues samples. On the other hand, we 
decided to study PMDs including of all sizes. As 
commented above, this implies that PMDs might 
be present in different genomic scale phenomena, 
from small to large ones. Thus, it will be needed 
in the future to split PMDs according to their 
length and study each subgroup as a single entity. 
In fact, our preliminary results demonstrate that 
there are differences in the distribution of some 
genomic features studied here for example, as 
commented above, an increase in LADs when 
PMDs are filtered as larger regions.  
 We have extensively characterized PMDs 
with several analyses, studying the distribution of 
different genomic features in PMDs with respect 
to non-PMDs and the whole plBC genome. 
Chromatin segmentation analysis revealed 
enrichment in heterochromatic regions and a large 
depletion in gene activity marks in PMDs (Figure 
3). This is in agreement with all the previous 
studies addressing the chromatin signature of 
PMDs. (Lister R, 2009; Hon GC, 2012; Marzese 
DM, 2014 and Hovestadt V, 2014). Furthermore, 
Berman NP, 2011, found that PMDs of colorectal 
cancer cell line overlapped with LADs, another 
established repressive chromatin mark (Gulen L, 
2008). We found a moderate genome-wide 
enrichment of LADs in PMDs, and an impressive 
overlap in the locus analyzed (Figure 4). 
However, as commented above, further splitting 
PMDs according to size could clarify the presence 
of LADs in PMDs of the plBC genome. All these 
correlations of PMDs with inactive chromatin 
states have been complemented with microarray 
and RNA-seq experiments, verifying that PMDs 
are regions with inactive genes (Schroeder DI, 
2013, Lister R 2009). Thus, it is clear that PMDs 
are regions characterized by chromatin repressive 
marks and poor gene expression. In addition to 
this, we found a strong decrease in CGIs. This 
depletion in CGIs can be explained by the 
observation that CGIs of the human genome exist 
mostly in a fully or unmethylated state (Deaton 
AM, 2011), and thus are excluded from the search 
for PMDs. Furthermore, CGIs have been shown to 
colocalise with the promoters of constitutively 
expressed genes (Illingworth RS, 2009), whereas 
PMDs are marked with repressed states (Figure 
3). Accordingly, we found a decrease in gene 
density in PMDs, and genes outside PMDs were 
enriched in BP related to active metabolism and B 
cell commitment (Supplementary Table 7). 
 When inducing a pluripotent state 
(iPSCc), Lister R, 2011 found that PMDs of 
differentiated cells were transformed to a fully 
methylated state, and the reprogramming process 
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was also able to reverse the transcriptional 
repression associated with the PMDs. Thus, 
PMDs are established in differentiated cells but 
not in embryonic or pluripotent cells. As 
previously stated, we found PMDs in a 
differentiated plasma B cell, and the genes inside 
PMDs showed a great enrichment in BPs involved 
in development and cell fate commitment. These 
results are consistent with recent studies reporting 
expanded repressed chromatin domains 
(H3K9me2, H3K9me3 and H3K27me3) in 
lineage-committed cells that selectively affect 
genes involved in pluripotency and development, 
suggesting that epigenetic mechanisms play a 
critical role in cellular differentiation and 
maintenance of the differentiated state (Wen B, 
2009; Hawkins RD, 2010). Additionally, they 
demonstrated that the expansion of those 
repressive modifications were associated with a 
decrease in DNA methylation in differentiated 
cells. We found that PMDs are enriched for 
chromatin repressive marks, and by definition are 
regions with an averaged lower DNA methylation. 
Furthermore, we have found that PMDs were 
regions in H1-hESC, (which have a fully 
methylated genome, Figure 1) extensively 
transcribed, extremely poor in repressive 
chromatin marks, and contained a great proportion 
of Polycomb genes, which are well known to be 
involved in developmental processes. Thus, all 
this data strongly suggest that the majority of 
demethylation in PBC during differentiation 
occurs in the form of PMDs (Figure 2), take place 
in regions with genes enriched in developmental 
BP, and those regions become blocks of 
heterochromatic regions in the committed cells. 
Our enrichment analysis also supports this notion, 
since we found that genes outside PMDs (which 
are marked with active state) are related to active 
metabolism and in BPs typical of committed B 
(Supplementary Table 7). We also demonstrated 
that PMDs are strongly depleted of DHS. In turn, 
regions depleted in DHS have been associated 
with heterochromatin and late replicating regions 
(Hansen RS, 2009), and late replication regions 
have been found to lose gradually DNA 
methylation (Aran D, 2010). Thus, it might be the 
case that PMDs, since they are heterochromatic 
regions depleted of gene activity and might 
replicate late in the cell (Figure 4), experience a 
gradually demethylation process which ultimately 
leads to a partially methylated state. Results from 
Gaidatzis D 2014, supports this notion. They 
found that in PMDs, and not outside, the 
methylation is, to a significant extent, determined 
by the specific local DNA sequence. They 
proposed that in PMDs there is a point where the 
concentration of DNA machinery becomes rate 
limiting, and it is at this point that DNA sequence 
preference becomes evident. It might be also the 
case that PMDs are the result of reducing the cost 
of methylation maintenance at the inactive and 
repressed chromatin portion of the genome, where 
a precise methylation level is presumably not 
essential. Collectively, these studies suggest that 
is likely that PMDs are secondary to, rather than 
causative of, heterochromatin formation. 
 Curiously, when looking at a particular 
locus on chromosome 10, we found that PMDs of 
the plBC genome overlapped hypomethylated 
regions in hypomethylaed myeloma cancer 
(Figure 4). This locus displayed the same features 
found in our genome-wide analysis of PMDs in 
12 
 
plBC, though with a greater overlap of LADs and 
also with late replication regions. Additionally, 
pairwise comparison of the plBC methylome and 
the hypomethylated myeloma revealed that a 
considerable fraction of hypomethylated sites of 
the myeloma were in a partially methylated state 
in plBC (Figure 4, bottom left), suggesting that 
our finding could be also the case for many 
different loci. This notion is consistent with other 
studies showing abnormalities in cancer related to 
PMDs. In fact, PMDs have been recently 
reviewed and noted as a prominent feature of 
tumour methylomes (Shen H, 2013). For instance, 
Berman BP, 2011, found PMDs in colorectal 
tumours relative to adjacent normal colon, and 
those PMDs were also found to overlap with 
LADs. In another study, Hansen KD, 2011 
identified regions with increased variability in 
methylation levels across cancer types, and these 
regions overlapped with PMDs. On the other 
hand, Hon GC et al (2012) found that PMDs in 
HMEC were the most likely regions to either gain 
or lose DNA methylation during tumorigenesis. In 
another study conducted by Hovestadt V, 2014, 
the authors found PMDs subgroup specificity in 
WNT and Group 3 medulloblasomas, and PMDs 
were found to have a significant increased somatic 
mutation rate compared to regions outside PMDs. 
Finally, PMDs were found in melanoma brain 
metastasis (MBM) patients, and a MBM-specific 
PMD was able to predict the prognosis of patients 
with melanoma (Marzese DM, 2014). 
Collectively, these studies manifest a major role 
of PMDs in cancer, altering the normal 
methylomes landscape and promoting 
tumorigenesis. Further studies will be needed to 
clarify the mechanisms by which these regions 
appear in some cancers and why PMDs present in 
normal cells are hotspots to either gain or loss 
methylation during tumorigenesis, and what are 
the consequences of losing or gaining  
methylation at that sides.  
MATERIALS AND METHODS 
Samples analyzed. 
WGBS-Seq of all the samples was performed as in 
Kulis M et al, (submitted) at the Centro Nacional 
d’Anàlisis Genòmica (CNAG) in Barcelona, Spain. 
Details for all samples are in Supplementary table 1. 
The data from Hansen KD, 2014 can be found in the 
original study. Briefly, we analyzed WGBS-Seq of the 
following samples: 6 monocytes, 4 granulocytes, 
1Naïve CD8+ T cell, 3 naïve B cell,1effector memory 
T cell, 3 adult Nautral killer Cells, 1 memory B cells,1 
class switch B cell, 2 central memory T cells, 1 
hypermethylated myeloma, and 1 hypomethylated 
myeloma and finally the differentiation dataset: 
progenitor B cell (PBC), a pre B cell (preBC),a naïve B 
cell (NBC),a germinal center B cell (GCBC), a 
memory B cell (MBC) and a plasma B cell (plBC)  
Data processing 
Analysis throughout the study were performed in R 
programming language (www.r-project.org), using core 
packages from Bioconductor. Custom Awk and bash 
scripts as well as Bedtools suite (Quinlan AR, 2010) 
were also used to perform the analysis and manage the 
data.  
Searching of PMDs in the methylomes 
As commented above, we used the MethylSeekR 
package (Burger L, 2013) to find PMDs in all the 
samples. Briefly, the distribution of α-values is 
calculated for one chromosome. α characterizes the 
distribution of methylation levels in sliding windows 
containing 101 consecutive CpGs along the genome. 
The α parameter is derived from modelling methylation 
by the number of BS-converted and BS-unconverted 
reads based on a symmetric beta binomial distribution: 
 
α-values smaller than 1 reflect a bimodal distribution of 
methylation, favouring either unmethylated or 
methylated states. On the other hand, α-values equal or 
greater than 1 indicate distributions of methylation 
values that are rather uniform or polarized towards 
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intermediate methylation levels, as in PMDs. 
Importantly, we used the shape of the distribution of α-
values instead of looking only at the proportion of 
windows greater than 1. Bimodal or long-tailed 
distributions of α-values are indicative of PMDs. Once 
the distribution is calculated, a two-state HMM is 
trained on the distribution and PMDs are found using 
the Viterbi algorithm. 
Functional characterization of PMDs. 
Chromatin segmentations of the GM12878 and H1-
hESC cell lines were downloaded from the European 
Bioinformatics Institute (EMBL) http://www.ebi.ac.uk/ 
.DHS data  for GM12878 was downloaded from the 
UCSC Genome Browser (Kent WJ, 2002) 
(https://genome-euro.ucsc.edu/) as well as CGI data. 
LADs data was also downloaded from UCSC (from 
TIG3 fibroblasts), as well as repetitive element 
annotation, with RepeatMasker. Uncertain assignments 
of repetitive elements were removed for the analysis. 
Finally, RefSeq gene annotation was downloaded also 
from UCSC. 
Gene Ontology enrichment analysis. 
We used the Bedtools suite to retrieve genes falling 
inside and outside of PMDs and those ones overlapping 
the borders of PMDs. GO enrichment analysis of genes 
present in each of the three groups were done using 
GOstats and biomaRt packages from Bioconductor. 
Genes without GO Terms were removed from the 
analysis. We used a cutoff of the FDR of 0.001, and a 
conditional overenrichment analysis was performed for 
all the three groups. 
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